Difelikefalin

Difelikefalin (Korsuva) is a real, FDA-approved peptide, a first-in-class kappa-opioid agonist engineered to stay out of the brain — treating a common, historically under-treated symptom of hemodialysis (chronic itch) without the sedation or abuse potential of a typical opioid drug.

A peptide built to stay outside the brain

Difelikefalin is a synthetic peptide agonist selective for kappa-opioid receptors, given a permanently charged, hydrophilic structure specifically so it does not meaningfully cross the blood-brain barrier. That distinction matters: most opioid-receptor drugs act centrally and carry sedation, euphoria, and abuse potential, while difelikefalin instead acts on kappa-opioid receptors on peripheral sensory neurons and immune cells — receptors implicated in the intense, chronic itch (pruritus) that affects a large share of patients on long-term hemodialysis, a symptom with no FDA-approved treatment of its own before this drug.

The approval and pivotal trial

The FDA approved difelikefalin (as Korsuva) on 23 August 2021 for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Approval rested on two identically designed placebo-controlled Phase 3 trials, KALM-1 and KALM-2. The published KALM-1 results (Fishbane et al., N Engl J Med 2020;382(3):222-232, PMID 31702883) found that 51.9% of 158 difelikefalin-treated patients had at least a 3-point reduction on the Worst Itching Intensity Numerical Rating Scale after 12 weeks of thrice-weekly intravenous dosing, versus 30.9% of 165 patients on placebo — a statistically significant and clinically meaningful difference, with a matching improvement in itch-related quality-of-life measures.

Safety

No boxed warning. The most common adverse reactions in trials were diarrhea, dizziness, vomiting, falls, and hyperkalemia. Despite acting on an opioid receptor, difelikefalin is not a DEA-scheduled controlled substance — a dedicated human abuse-potential study found its effects indistinguishable from placebo and well below those of pentazocine, a Schedule IV comparator, consistent with its peripherally restricted design. It carries no analgesic indication and is not a general-purpose itch or pain drug.

Current status

Still marketed by CSL Vifor as Korsuva injection, administered by dialysis-clinic staff as part of the dialysis session itself rather than self-injected at home; no generic version yet. It is also under separate clinical study for pruritus linked to chronic liver disease and for notalgia paresthetica, neither of which is an approved use.